Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
PR Newswire - November 22, 1995 .
"During the third quarter, we launched a Phase I trial of AR177 for HIV infection, as well as a Phase II trial of Tretinoin(LF) for acute promyelocytic leukemia. The initiation of these trials is an important step in executing our commercialization strategy to capitalize on Aronex's broad technology base and to diversify risk," said James M. Chubb, Ph.D., President of the Company. "AR177 and Tretinoin are two of six Aronex products in clinical development, contributing to a strong and diverse portfolio for the Company," added Dr. Chubb.
"Also in the third quarter, Aronex received funding from the National Institute of Allergy and Infectious Diseases for the development of two novel compounds that have emerged from Aronex's pipeline: AR177 for HIV, and AR132 for cytomegalovirus."
Aronex anticipates the initiation of a Phase III trial of Nystatin(LF), for systemic fungal infections, and a Phase II trial of its solid tumor drug, Annamycin(LF), in early 1996. The Company continues to pursue corporate alliances, such as the collaborations with Genzyme Corporation and Hoechst AG, for the development of several compounds in the preclinical or early clinical stage.
For the nine months ended September 30, 1995, Aronex reported a net loss of $13.8 million, or $1.24 per share, compared with a net loss of $6.7 million, or $0.65 per share for the first nine months of 1994. Total revenues for the nine months ended September 30, 1995, comprised of income and contract research, were $780,000 compared with $567,000 for the same period in 1994. Research and development revenues from affiliates for the first nine months of 1995 were $491,000, compared to $197,000 for the nine months ended September 30, 1994. The increase in revenues is a result of pharmaceutical development being conducted in collaboration with its corporate partners Hoechst AG, Genzyme Corporation and RGene Therapeutics, Inc.
Aronex Pharmaceuticals, Inc. is developing and commercializing innovative pharmaceuticals for treating cancer and infectious diseases. Aronex has several products in clinical development including Nystatin(LF) for the treatment of systemic fungal infections; Annamycin(LF) for the treatment of solid tumors; and AR177 for HIV infection. The Company has a collaboration with Genzyme Corporation to develop Tretinoin(LF) for the treatment of Kaposi's sarcoma and acute promyelocytic leukemia.
ARONEX PHARMACEUTICALS, INC. (A development stage company) CONDENSED STATEMENTS OF OPERATIONS (All amounts in thousands, except loss per share data) (Unaudited)
Nine Months Ended Three months Ended September 30, September 30, 1995 1994 1995 1994
Revenues:
Interest income $289 $370 $76 $144
Research and Development Revenue from affiliates 491 197 200 107
Total revenues 780 567 276 251
Expenses:
Research and development 5,452 5,595 1,910 1,941 Charge for purchase of in-process research and development 7,419 --- 7,419 ---
General and administrative 1,534 1,540 718 407
Interest expense 144 141 46 55
Total expenses 14,549 7,276 10,093 2,403
Net loss $(13,769) $(6,709) $(9,817) $(2,152)
Net loss per share $(1.24) $(0.65) $(0.80) $(0.20)
Weighted average common shares outstanding 11,071 10,272 12,297 10,302
CONDENSED BALANCE SHEETS
Sept. 30, Dec. 31, 1995 1994 (Unaudited)
ASSETS Current assets:
Cash and cash equivalents $3,589 $1,426 Securities held to maturity 5,735 7,006 Prepaid expenses and other assets 365 415
Total current assets 9,689 8,847
Available-for-sale securities $1,699 $1,587 Furniture, equipment and leasehold improvements, net 3,012 2,174
Investment in RGene Therapeutics, Inc. 125 350
Total assets $14,525 $12,958
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities 1,896 1,080 Total long-term liabilities 1,330 1,218 Total stockholders' equity 11,299 10,660 Total liabilities and stockholders' equity $14,525 $12,958
CONTACT: Terance A. Murnane, Controller of Aronex Pharmaceuticals, Inc., 713-367-1666, or Michelle L. Linn, Sr. Account Executive of Feinstein Partners Inc., 617-577-8110/ 12:30 EST
Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951122
PR951136
Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .